Correction to: Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions

被引：0
|
作者：
Aasha Harish
Stanley A. Schwartz
机构：
[1] University at Buffalo,Division of Allergy and Immunology, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences
来源：
Clinical Reviews in Allergy & Immunology | 2020年 / 59卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The original version of this article unfortunately contained a mistake in the fifth paragraph of the “Conclusion” section.
引用
收藏
页码：273 / 273
相关论文
共 50 条
  • [41] Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis
    Plotz, S
    Simon, H
    Darsow, U
    Simon, D
    Vassina, E
    Yousefi, S
    Hein, R
    Smith, T
    Behrendt, H
    Ring, J
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (24): : 2334 - 2339
  • [42] Occurrence of Sezary syndrome following the initiation of anti-IL-5 drug
    Barre, Mathilde
    Amatore, Florent
    Avenin, Morgan
    Gorvel, Laurent
    Olive, Daniel
    Delaporte, Emmanuel
    EUROPEAN JOURNAL OF CANCER, 2021, 156 : S41 - S42
  • [43] ANTI-IL-5 AGENTS IN THE TREATMENT OF EOSINOPHILIC COPD: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Tan, Irene Rosellen
    Villalobos, Ralph Elvi
    Jaen, Anjulimay
    Wang, Aileen
    CHEST, 2018, 154 (04) : 759A - 759A
  • [44] Influence of anti-interleukin (IL)-5/anti-IL-5 receptor-α treatment on work productivity in patients with severe eosinophilic asthma
    Drick, Nora
    Brinkmann, Lina
    Fuge, Jan
    Welte, Tobias
    Suhling, Hendrik
    ERJ OPEN RESEARCH, 2023, 9 (03)
  • [45] Mepolizumab. Anti-IL-5 monoclonal antibody therapy in patients with Severe Eosinophilic Asthma
    Buttler, Bogna
    Dewor, Robert
    ALERGIA ASTMA IMMUNOLOGIA, 2018, 23 (03): : 137 - 142
  • [46] The effect of anti-IL-5 biologics on lung function in adults with severe eosinophilic asthma.
    Wallbanks, Samuel
    Thomas, Maximillian
    Cooper, Brendan
    Sullivan, Julie
    White, Lisa
    Pillai, Anilkumar
    Mansur, Adel
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [47] Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media
    Iino, Yukiko
    Takahashi, Eli
    Ida, Saeko
    Kikuchi, Saori
    AURIS NASUS LARYNX, 2019, 46 (02) : 196 - 203
  • [48] Relationship between baseline fraction of exhaled nitric oxide (FeNO) and response to anti-IL-5/5R therapies in severe eosinophilic asthma (SEA)
    Kavanagh, Joanne
    Hearn, Andrew
    Roxas, Cris
    Green, Linda
    Fernandes, Marianna
    Thomson, Louise
    Payne, Victoria
    D'Ancona, Grainne
    Kent, Brian
    Dhariwal, Jaideep
    Nanzer-Kelly, Alexandra
    Jackson, David
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [49] Occurrence of Sézary syndrome following the initiation of anti-IL-5 treatment
    Mathilde Barré
    Florent Amatore
    Morgan Avenin
    Laurent Gorvel
    Daniel Olive
    Emmanuel Delaporte
    European Journal of Dermatology, 2022, 32 : 419 - 420
  • [50] Successful use of anti IL5 targeted therapy (Mepolizumab) in two cases of hypereosinophilic syndrome from India
    Chopra, Manu
    Pramanik, Suman
    Mukherjee, Subhro
    Chopra, Meenakshi
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
12345